Category: 1211587-01-7

In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 1211587-01-7, name is 5-Chloropyridazine-3-carboxylic acid, introducing its new discovery. Product Details of 1211587-01-7

Angiotensin II receptor antagonists

Compounds are disclosed having the formula: STR1 The compounds of the invention are angiotensin II receptor antagonists.

We¡¯ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 1211587-01-7, and how the biochemistry of the body works.Product Details of 1211587-01-7

Reference£º
Pyridazine – Wikipedia,
Pyridazine | C4H4N2037 – PubChem

 

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1211587-01-7,5-Chloropyridazine-3-carboxylic acid,as a common compound, the synthetic route is as follows.

The carboxylic acid (243 mg, 1.53 mmol) was dissolved in ~15 mL of ethanol and treated with 24 mg (0.2 mmol) of dimethylaminopyridine (DMAP) followed by 324 mg (1.69 mmol) 1-(3-dimethylaminopropyl-3-ethylcarbodiimide hydrochloride (EDCl). The reaction was stirred at ambient temperature for 4 hours and then worked up by the procedure described in Example 166A. The crude product was purified by flash chromatography on silica gel to give 150 mg (52%) of the title compound as a white crystalline solid. 1 H NMR (CDCl3, 300 MHz) delta 1.45 (t, 3H), 4.55 (q, 2H), 7.65 (d, 1H), 8.15 (d, 1H). MS (DCl/NH3) m/e 187/189 (M+H)+, 204/206 (M+H+NH3)+., 1211587-01-7

1211587-01-7 5-Chloropyridazine-3-carboxylic acid 19792063, apyridazine compound, is more and more widely used in various fields.

Reference£º
Patent; Abbott Laboratories; US5250548; (1993); A;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem